Swissmedic Authorises CSL’s HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
On Jan. 15, 2024, CSL announced that Swissmedic had authorised HEMGENIX® (etranacogene dezaparvovec), the first and currently only gene…
On Jan. 15, 2024, CSL announced that Swissmedic had authorised HEMGENIX® (etranacogene dezaparvovec), the first and currently only gene…
On Jan. 10, 2024, an National Institutes of Health (NIH) supported study announced an n atlas revealing the…
On Jan. 9, 2024, biologists in Alaska have confirmed the first case of a polar bear dying after…
On Jan. 9, 2024, the Institute for Health Metrics and Evaluation (HHMI) reported that despite a gradual decline…
On Jan. 9, 2024, Biogen and Eisai announced that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody ‘LEQEMBI’…
On Jan. 5, 2024, the U.S. Food and Drug Administration (FDA) authorized Florida’s Agency for Health Care Administration’s…
On Dec. 21, 2023, CSL and and Arcturus Therapeutics announced the results of a Phase 3 study showing…
On Dec. 19, 2023, a research team led by Rice University reported they found that the atoms of…
On Dec. 18, 2023, W. Kimryn Rathmell, M.D., Ph.D., began work as the 17th director of the National…
On Dec. 18, 2023, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization…
On Dec. 14, 2023, the Department of Energy’s Pacific Northwest National Laboratory announced that it had created the…
On Dec. 14, 2023, the University of Alberta announced that a study published in Nature sheds light on…
On Dec. 14, 2023, Pfizer announced it had completed the acquisition of Seagen, a global biotechnology company based…
On Dec. 14, 2023, Biogen and Sage Therapeutics announced ZURZUVAE (zuranolone) 50 mg (two 25 mg capsules per…
On Dec. 13, 2023, National Institute of Allergy and Infectious Diseases (NIAID) scientists announced findings published in the…
On Dec. 13, 2023, for the first time ever, an international team of researchers announced they had created…
On Dec. 13, 2023, the Allen Institute and collaborators announced that after six years and 32 million cells,…
On Dec. 8, 2023, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing…
On Dec. 8, 2023, Vertex Pharmaceuticals and CRISPR Therapeutics announced that the U.S. Food and Drug Administration (FDA)…
On Dec. 8, 2023, bluebird bio announced the U.S. commercial launch of its LYFGENIA’ (lovotibeglogene autotemcel, also known…
On Dec. 6, 2023, Anixa Biosciences announced updated positive results from the Phase 1 clinical trial of its…
On Dec. 5, 2023, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid XBB.1.5 Vaccine (Recombinant…
On Dec. 4 2023, the University of Wisconsin-Madison researchers announced that while analyzing data from wastewater samples collected…
On Dec. 1, 2023, the World Health Organization (WHO) announced that the International Health Regulations National Focal Point…
On Nov. 30, 2023, in a momentous landmark for medical research, UK Biobank announced that it had unveiled…
On Nov. 29, 2023, Novavax’s partner, SK bioscience, announced that Novavax’s updated COVID-19 vaccine (NVX-CoV2601) had received Emergency…
On Nov. 28, 2023, Novavax announced that Nuvaxovid XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) had been granted Emergency Use Listing…
On Nov. 28, 2023, Emergent BioSolutions announced that the Biomedical Advanced Research and Development Authority (BARDA) within the…
On Nov. 27, 2023, University of Wisconsin-Madison researchers released a study that showed COVID-19 caused an alarming surge…
On Nov. 17, 2023, Masimo announced that the Masimo W1 medical watch has received FDA 510(k) clearance for…